Madrigal Pharmaceuticals Incorporated (NASDAQ:MDGL) Reports Decline in Sellers; Strong Momentum for Longs

February 15, 2018 - By Richard Conner

 Madrigal Pharmaceuticals Incorporated (NASDAQ:MDGL) Reports Decline in Sellers; Strong Momentum for Longs

The stock of Madrigal Pharmaceuticals Incorporated (NASDAQ:MDGL) registered a decrease of 5.2% in short interest. MDGL’s total short interest was 269,700 shares in February as published by FINRA. Its down 5.2% from 284,500 shares, reported previously. With 66,400 shares average volume, it will take short sellers 4 days to cover their MDGL’s short positions. The short interest to Madrigal Pharmaceuticals Incorporated’s float is 5.64%.

The stock increased 0.79% or $1.03 during the last trading session, reaching $131.15. About 133,580 shares traded. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $1.84 billion. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

More notable recent Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news were published by: Seekingalpha.com which released: “Madrigal Continues Its Success With Another High Target Indication” on February 09, 2018, also Seekingalpha.com with their article: “Madrigal Pharmaceuticals: Elucidating The Positive Outcomes Of The Phase 2 …” published on February 11, 2018, Seekingalpha.com published: “Madrigal Pharmaceuticals: Buy The Secondary” on December 20, 2017. More interesting news about Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) were released by: Fool.com and their article: “Why Madrigal Pharmaceuticals Stock Is On Fire Today” published on December 06, 2017 as well as Seekingalpha.com‘s news article titled: “Madrigal Pharmaceuticals: Buy The Dip” with publication date: February 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.